OncoMatch/Clinical Trials/NCT06636617
177Lu-JH04 in Patients with FAP-Positive Tumors
Is NCT06636617 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including 3.70 GBq (100 mCi) of 177Lu-JH04 and 5.55 GBq (150 mCi) of 177Lu-JH04 for patients with advanced metastatic fap-positive tumors.
Treatment: 3.70 GBq (100 mCi) of 177Lu-JH04 · 5.55 GBq (150 mCi) of 177Lu-JH04 · 7.40 GBq (200 mCi) of 177Lu-JH04 — This is a pilot study to assess the dosimetry, toxicity and response of 177Lu-JH04, a new FAP-targeted radiopharmaceutical, in patients with FAP-Positive Tumors. All patients underwent 68Ga-FAPI PET/CT for selection and were successively divided into three groups of 3 people each.The three groups received successively an approximately 3.70 GBq (100 mCi), 5.55 GBq (150 mCi) and 7.40 GBq (200 mCi) of 177Lu-JH04 up to 4 cycles.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: FAP high expression (high)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radionuclide therapy
received other radionuclide therapy in the past 6 months
Cannot have received: chemotherapy
received chemotherapy...in the past 28 days
Cannot have received: radiotherapy
received...radiotherapy...in the past 28 days
Cannot have received: anti-tumor treatments
received...other anti-tumor treatments in the past 28 days
Lab requirements
Blood counts
adequate haematological function
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify